Weekly Watched Assets — 2026-07-05
14 high-conviction US stocks identified from monthly sentiment analysis.
TEAM — Atlassian Corp.
1W +12.3% | 1M -23.1% | 3M +22.8% | YTD -45.8%
"structural re-rating"
Thesis: The investment thesis centers on a deep value inflection driven by explosive earnings revisions, a Zacks Rank #1, and extreme undervaluation amid forced selling, creating a time-sensitive window for structural re-rating. Near-term catalysts including AI monetization and index reclassification provide clear upside visibility. Conviction: 98% (high)
GH — Guardant Health Inc. Common Stock
1W +17.5% | 1M +29.1% | 3M +79.0% | YTD +65.1%
"seismic leap"
Thesis: GH is positioned at a transformative regulatory and commercial inflection point, with national coverage determination and UnitedHealthcare's 100M+ patient expansion serving as high-impact catalysts. The stock's momentum reflects early institutional accumulation ahead of potential market-destabilizing growth. Conviction: 96% (high)
TTAN — ServiceTitan Inc. Class A Common Stock
1W +23.5% | 1M +4.4% | 3M +24.4% | YTD -22.9%
"one of the most extreme dislocations in the tech sector"
Thesis: TTAN trades at a 40.1% discount to intrinsic value despite a dominant AI-enabled platform and growing transaction data moat. Monetization of 'Karen' AI and real revenue traction create a rare non-disruptable platform narrative with asymmetric risk/reward. Conviction: 97% (high)
IX — ORIX Corporation
1W +1.5% | 1M +0.6% | 3M +30.1% | YTD +32.5%
"transformative capital return move that materially boosts per-share value"
Thesis: A JPY 250 billion buyback with share cancellation acts as a powerful near-term catalyst, signaling strong fundamental acceleration and U.S. integration. The deep value inflection is supported by extraordinary earnings revision momentum and institutional confidence. Conviction: 96% (high)
ROP — Roper Technologies, Inc.
1W +9.6% | 1M +8.2% | 3M +2.0% | YTD -16.0%
"one of the most powerful sentiment indicators in the sector this week"
Thesis: ROP presents a rare contrarian opportunity in the software/industrial space, driven by high-conviction insider activity, extreme undervaluation, and imminent regulatory catalysts. The potential for rapid re-rating is amplified by its immunology franchise's transformative potential. Conviction: 96% (high)
BSX — Boston Scientific Corporation
1W +2.1% | 1M -5.3% | 3M -28.1% | YTD -52.3%
"catastrophic disconnect between fundamentals and market sentiment"
Thesis: Despite a severe FDA recall overhang, BSX shows strong fundamentals and near-term catalysts including Penumbra's Thunderbolt clearance and MiRus SIEGEL TAVR development. The catastrophic disconnect between sentiment and fundamentals creates a multi-bagger contrarian recovery case. Conviction: 95% (high)
ELV — Elevance Health, Inc.
1W +7.9% | 1M +7.9% | 3M +39.5% | YTD +19.2%
"structural re-rating"
Thesis: Seth Klarman’s $373M investment and the CMS lawsuit serve as pivotal catalysts for a structural re-rating, validating ELV's strategic shift. Momentum is strong, and the deep value inflection supports a high-conviction, multi-bagger recovery thesis. Conviction: 95% (high)
NYT — New York Times Company (The) Common Stock
1W +7.7% | 1M -1.9% | 3M -13.8% | YTD +6.3%
"central beneficiary of AI-driven attention economy monetization"
Thesis: Berkshire Hathaway’s near-tripling of its stake provides institutional validation, while the landmark lawsuit against OpenAI and Microsoft unlocks transformative AI licensing revenue potential. The thesis combines low-risk accumulation with high-return optionality. Conviction: 95% (high)
PCT — PureCycle Technologies, Inc.
1W -3.7% | 1M -40.8% | 3M +40.4% | YTD -15.0%
"giving PCT a near-monopoly in a high-growth segment"
Thesis: PCT holds a near-monopoly in food-grade #5 plastic recycling, with NJDEP certification acting as a key commercial catalyst. The market’s indiscriminate selling has created a dangerous disconnect between execution and perception, offering contrarian upside. Conviction: 95% (high)
NBIX — Neurocrine Biosciences Inc. Common Stock
1W +6.1% | 1M +12.5% | 3M +32.4% | YTD +23.9%
"paradigm shift in pediatric endocrine therapy"
Thesis: NBIX is leveraging groundbreaking clinical results to build a rare sustainable revenue moat in pediatric endocrinology and rare diseases. The transformative foothold in congenital adrenal hyperplasia provides a clear path to blockbuster potential and investor confidence inflection. Conviction: 94% (high)
BWXT — BWX Technologies Inc. Common Stock
1W -6.7% | 1M +2.0% | 3M -11.0% | YTD +5.3%
"paradigm shift in BWXT’s business model"
Thesis: BWXT is undergoing a paradigm shift from parts supplier to technology enabler, fueled by the $1.4B DOE contract and mPower™ licensing, creating a high-margin, royalty-backed SMR growth engine. The deep valuation disconnect suggests significant re-rating potential. Conviction: 94% (high)
CTSH — Cognizant Technology Solutions Corporation
1W +7.2% | 1M -23.9% | 3M -32.4% | YTD -47.7%
"a credible move positioning CTSH as a first-mover in sovereign AI infrastructure"
Thesis: CTSH is emerging as a foundational enabler in the agentic AI era, with strategic partnerships and sovereign AI infrastructure positioning. Pzena’s stake increase during the selloff signals contrarian conviction in undervaluation and future re-rating. Conviction: 93% (high)
ZTO — ZTO Express (Cayman) Inc.
1W +5.9% | 1M +2.2% | 3M -6.0% | YTD +9.3%
"creating a high-conviction long-term value and growth opportunity"
Thesis: ZTO combines operational outperformance with a fully funded $1.5B buyback, creating a high-conviction long-term value opportunity despite sentiment weakness. The PEG of 0.84 highlights a severe fundamental-market disconnect. Conviction: 95% (high)
VST — Vistra Corp.
1W -10.0% | 1M -4.2% | 3M +0.1% | YTD -8.3%
"unquestioned infrastructure backbone of the AI era"
Thesis: VST is the unquestioned infrastructure backbone of the AI era, with transformative PPAs and exceptional ROE execution. Despite deep undervaluation, recent negative price momentum and lack of near-term momentum indicators reduce near-term conviction. Conviction: 92% (high)